<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>2375</number>
    <updateDate>2023-01-11T13:44:08Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:44:08Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2019-04-29</introducedDate>
    <congress>116</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 165, Number 69 (Monday, April 29, 2019)][House]From the Congressional Record Online through the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]By Mr. NADLER:H.R. 2375.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8 of the United States Constitution[Page H3303]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2019-04-30T19:16:06Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Discharged from</name>
            <date>2020-12-24T15:25:19Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2019-04-29T18:00:22Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hsju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2020-12-24T15:25:11Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2019-04-30T20:46:17Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2019-04-29T18:00:17Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <committeeReports>
      <committeeReport>
        <citation>H. Rept. 116-693</citation>
      </committeeReport>
    </committeeReports>
    <relatedBills>
      <item>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <congress>116</congress>
        <number>64</number>
        <type>S</type>
        <latestAction>
          <actionDate>2019-01-09</actionDate>
          <text>Read twice and referred to the Committee on the Judiciary.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Competitive DRUGS Act of 2019</title>
        <congress>116</congress>
        <number>1344</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-03-25</actionDate>
          <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2020-12-24</actionDate>
        <text>Placed on the Union Calendar, Calendar No. 576.</text>
        <type>Calendars</type>
        <actionCode>H12410</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <calendarNumber>
          <calendar>U00576</calendar>
        </calendarNumber>
      </item>
      <item>
        <actionDate>2020-12-24</actionDate>
        <text>Committee on Energy and Commerce discharged.</text>
        <type>Discharge</type>
        <actionCode>H12300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2020-12-24</actionDate>
        <text>Committee on Energy and Commerce discharged.</text>
        <type>Committee</type>
        <actionCode>5500</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2020-12-24</actionDate>
        <text>Reported by the Committee on Judiciary. H. Rept. 116-693, Part I.</text>
        <type>Committee</type>
        <actionCode>H12200</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2020-12-24</actionDate>
        <text>Reported by the Committee on Judiciary. H. Rept. 116-693, Part I.</text>
        <type>Committee</type>
        <actionCode>5000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2019-04-30</actionDate>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Ordered to be Reported by Voice Vote.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-04-30</actionDate>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Committee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-04-30</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-04-29</actionDate>
        <text>Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2019-04-29</actionDate>
        <text>Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2019-04-29</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2019-04-29</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>N000002</bioguideId>
        <fullName>Rep. Nadler, Jerrold [D-NY-10]</fullName>
        <firstName>JERROLD</firstName>
        <lastName>NADLER</lastName>
        <party>D</party>
        <state>NY</state>
        <district>10</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001093</bioguideId>
        <fullName>Rep. Collins, Doug [R-GA-9]</fullName>
        <firstName>Doug</firstName>
        <lastName>Collins</lastName>
        <party>R</party>
        <state>GA</state>
        <district>9</district>
        <sponsorshipDate>2019-04-29</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001084</bioguideId>
        <fullName>Rep. Cicilline, David N. [D-RI-1]</fullName>
        <firstName>David</firstName>
        <lastName>Cicilline</lastName>
        <party>D</party>
        <state>RI</state>
        <middleName>N.</middleName>
        <district>1</district>
        <sponsorshipDate>2019-04-29</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001068</bioguideId>
        <fullName>Rep. Cohen, Steve [D-TN-9]</fullName>
        <firstName>Steve</firstName>
        <lastName>Cohen</lastName>
        <party>D</party>
        <state>TN</state>
        <district>9</district>
        <sponsorshipDate>2019-04-30</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M001187</bioguideId>
        <fullName>Rep. Meadows, Mark [R-NC-11]</fullName>
        <firstName>Mark</firstName>
        <lastName>Meadows</lastName>
        <party>R</party>
        <state>NC</state>
        <district>11</district>
        <sponsorshipDate>2019-05-07</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <cboCostEstimates>
      <item>
        <pubDate>2019-05-09T15:29:00Z</pubDate>
        <title>H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act</title>
        <url>https://www.cbo.gov/publication/55225</url>
        <description>As ordered reported by the House Committee on the Judiciary on April 30, 2019</description>
      </item>
    </cboCostEstimates>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Civil actions and liability</name>
        </item>
        <item>
          <name>Competition and antitrust</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Contracts and agency</name>
        </item>
        <item>
          <name>Federal Trade Commission (FTC)</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>Judicial review and appeals</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Marketing and advertising</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2019-04-29</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2021-07-29T13:03:12Z</updateDate>
        <text><![CDATA[ <p><b>Preserve Access to Affordable Generics and Biosimilars Act</b></p>This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. <p>An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.</p> <p> When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.</p> <p>The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.</p>]]></text>
      </summary>
      <summary>
        <versionCode>08</versionCode>
        <actionDate>2020-12-24</actionDate>
        <actionDesc>Reported to House, Part I</actionDesc>
        <updateDate>2021-09-01T19:17:39Z</updateDate>
        <text><![CDATA[ <p><b>Preserve Access to Affordable Generics and Biosimilars Act</b></p> This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. <p>An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.</p> <p> When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.</p> <p>The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.</p>]]></text>
      </summary>
    </summaries>
    <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.</title>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House</titleType>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Reported in House</type>
        <date>2020-12-24T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr2375rh/xml/BILLS-116hr2375rh.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in House</type>
        <date>2019-04-29T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr2375ih/xml/BILLS-116hr2375ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2020-12-24</actionDate>
      <text>Placed on the Union Calendar, Calendar No. 576.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
